Standards & guidance

Filter Standards and Guidance documents

Page 5 of 13

FSRH CEU Guidance: Drug Interactions with Hormonal Contraception (May 2022)

09 May 2022

This FSRH Guidance provides evidence-based recommendations and good practice points for health professionals on drug Interaction with Hormonal Contraception. It is intended for use by health professionals working in sexual and reproductive health, general practice, and obstetric and gynaecology settings.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

FSRH CEU Statement: CVR availability and Dispensing - Jan 2022

11 January 2022

This FSRH Satement notes the availability and dispensive of the combined vaginal contraceptive rings in the UK.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Resource: New one-handed, reloadable 52mg levonorgestrel-releasing intrauterine system

10 November 2021

Benilexa® (Gedeon Richter) - a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) with a reloadable one-handed insertion device - is now available in the UK. Benilexa is licensed for 6 years of use for contraception. It is not licensed for endometrial protection as part of HRT. This FSRH CEU Resource provides a table which compares the product characteristics of LNG-IUS devices currently available in the UK, Benilexa®, Levosert®, Mirena®, Kyleena® and Jaydess®.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH Clinical Statement - DSG-POP as Pharmacy Medication

21 July 2021

This FSRH Statement reviews two desogestrel 75mcg progestogen-only pill (POP) available over-the-counter as Pharmacy Medicines.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH Statement: Pain associated with insertion of intrauterine contraception - June 2021

30 June 2021

Recent media reports have highlighted cases of individuals who have experienced distressing intrauterine contraception (IUC) fitting. Read and download the FSRH statement on pain associated with intrauterine contraception.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Statement: Contraception for Women with Eating Disorders (May 2021)

10 May 2021

Sexually active women of reproductive age with eating disorders require effective contraception despite the fact that amenorrhoea and anovulation are common in this population. This statement provides clinicians with a resource for best helping women with eating disorders choose the most appropriate and acceptable contraception for them.Download and save the document here.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Statement: Response to Recent Publication Turok et al. (2021) - February 2021

09 February 2021

This statement is a response to a study published in the New England Journal of Medicine, suggests that a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) is non-inferior to a T380A copper IUD (Cu-IUD) for emergency contraception (EC).

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU statement Levosert 6 year license for contraception - Feb 2021

08 February 2021

This statement notes that the Levosert® 52mg LNG-IUS has been licensed for contraceptive use for 6 years. Levosert remains licensed for 5 years for management of heavy menstrual bleeding and is not licensed for endometrial protection as part of HRT.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Response to study: Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme inducing antibiotics and hormonal contraceptives - February 2021

02 February 2021

This statement is a response to a new paper published in BMJ Evidence Based Medicine Journal suggesting that antibiotics may lessen the effectiveness of hormonal contraception.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date